AstraZeneca said Baxfendy (baxdrostat) was recommended for EU approval for adults with uncontrolled hypertension. If approved, it would be the EU’s first and only aldosterone synthase inhibitor; two Phase III trials showed reductions of 15.7 mmHg and 16.6 mmHg in systolic blood pressure.
AZN · Astrazeneca PLC · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
AstraZeneca’s Imfinzi plus EV (enfortumab vedotin) received US approval for perioperative treatment of adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy. The VOLGA Phase III trial showed 49% lower recurrence risk and 42% lower death risk.
AstraZeneca PLC reported that Klygefa (gefurulimab) received European Union (EU) approval as an add-on to standard therapy for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, based on positive PREVAIL Phase III trial results.
AstraZeneca PLC admitted 11,948 further securities to the London Stock Exchange - Main Market, bringing total securities in issue to 1,551,065,237; they were issued between 1 October 2026 to 31 October 2026 under employee share schemes.
AstraZeneca PLC reports 1,551,065,237 total voting rights as at 31 October 2026, with no shares held in Treasury.
AstraZeneca reported 9M 2026 total revenue up 7% at constant exchange rates and Core EPS up 14%, supported by double-digit growth in Oncology, R&I and Rare Disease.
AstraZeneca and Daiichi Sankyo’s Enhertu won EU approval on 27 October 2026 for residual HER2-positive early breast cancer; DESTINY-Breast05 showed a 53% reduction in recurrence or death, and a $75 million milestone is due to Daiichi Sankyo.
AstraZeneca PLC’s Ultomiris received accelerated approval in the US on 22 October 2026 as the first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy, showing a 43.4% reduction versus placebo at 34 weeks.
AstraZeneca completed its $2 billion equity investment in Summit Therapeutics on 5 October 2026, accelerating development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, and planning broader combination programmes.
AstraZeneca entered a clinical collaboration agreement with Daiichi Sankyo and Summit Therapeutics to evaluate Datroway with ivonescimab across multiple tumour types, beginning with a Phase III trial in 1st-line triple-negative breast cancer.
AstraZeneca PLC issued 9,828 fully fungible Ordinary Shares of $0.25 each between 1 September 2026 and 30 September 2026 under employee share schemes; admission to the London Stock Exchange - Main Market brought total securities in issue to 1,551,053,289.
AstraZeneca PLC reported 1,551,053,289 total voting rights as at 30 September 2026, based on 1,551,053,289 ordinary shares of US$0.25, with no shares held in Treasury.
AstraZeneca announced a $2 billion equity investment in Summit Therapeutics and a clinical collaboration to combine ivonescimab with sonesitatug vedotin in gastrointestinal cancers, with trials intended to begin imminently and broader ADC combinations planned.
AstraZeneca PLC announced European Commission approval of Trixeo as maintenance treatment for asthma in patients 12 years and older uncontrolled on medium-dose ICS/LABA, following positive KALOS and LOGOS Phase III trial results showing improved lung function and reduced severe exacerbations.
AstraZeneca’s Klygefa received a positive CHMP recommendation for EU approval as an add-on to standard therapy for adults with anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis.
AstraZeneca’s Enhertu was recommended for EU approval for residual HER2-positive early breast cancer; DESTINY-Breast05 found a 53% reduction in invasive disease recurrence or death versus T-DM1.